Seelos amends Lind note (principal +$1.25M) and issues 4M warrants; authorized shares doubled to 480M

SEELOS THERAPEUTICS, INC.

Lind Note principal increased by $1.25M to $17.75M; May-Sept 2023 payments may be made in cash and stock.
Issued 1M restricted shares to Lind and 4M warrants (exercise $1.06) to other investors as consideration.
Stockholders approved increase in authorized common shares from 240M to 480M.
Leak-out provisions restrict selling by Lind and other holders until Sept 2023 or SLS-002 data release.
Annual meeting: directors Dalesandro and Pascoe elected; KPMG ratified; say-on-pay advisory vote passed.

item 1.01 item 3.02 item 3.03 item 5.03 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

SEELOS THERAPEUTICS, INC.: Amended Articles of Incorporation to increase authorized shares of Common Stock from 240,000,000 to 480,000,000 (effective 2023-05-18).

Change: charter amendment
Effective: 2023-05-18

Exact text from the filing

On May 18, 2023, the Company filed a Certificate of Amendment to the Articles (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada to increase the number of authorized shares of Common Stock from 240,000,000 to 480,000,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

SEELOS THERAPEUTICS, INC. shareholders approved To elect two Class III directors, Margaret Dalesandro, Ph.D. and Richard W. Pascoe, nominated by the Company’s Board of Directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. at the 2023-05-18 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-18

Exact text from the filing

Proposal No. 1: To elect two Class III directors, Margaret Dalesandro, Ph.D. and Richard W. Pascoe, nominated by the Company’s Board of Directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Nominee For Withheld Broker Non-Votes Margaret Dalesandro, Ph.D. 45,742,271 16,787,800 23,504,999 Richard W. Pascoe 44,352,245 18,177,826 23,504,999

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

SEELOS THERAPEUTICS, INC. shareholders approved To approve an amendment to the Company’s Articles to increase the number of authorized shares of Common Stock to a total of 480,000,000. at the 2023-05-18 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-05-18

Exact text from the filing

Proposal No. 4 : To approve an amendment to the Company’s Articles to increase the number of authorized shares of Common Stock to a total of 480,000,000. For Against Abstentions 65,747,011 19,310,768 977,291

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

SEELOS THERAPEUTICS, INC. shareholders approved To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-18 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-18

Exact text from the filing

Proposal No. 2: To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstentions 79,992,858 5,498,430 543,782

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

SEELOS THERAPEUTICS, INC. shareholders approved To conduct an advisory (non-binding) vote on executive compensation. at the 2023-05-18 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-18

Exact text from the filing

Proposal No. 3 : To conduct an advisory (non-binding) vote on executive compensation. For Against Abstentions Broker Non-Votes 43,555,540 17,176,340 1,798,191 23,504,999

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001104659-23-062732

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.